Broadfin Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

Broadfin Capital’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-105,780	Closed	-$4.46M	–	89
2015 Q4	$4.46M	Sell	105,780 -25,000	-19%	-$1.19M	0.27%	70
2015 Q3	$7.17M	Buy	130,780 +6,185	+5%	+$613K	0.4%	58
2015 Q2	$13.7M	Sell	124,595 -4,780	-4%	-$444K	0.74%	39
2015 Q1	$12.3M	Buy	+129,375	New	+$9.13M	0.96%	28

Other funds holding GNCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Broadfin Capital's GNCA Position: Q1 2016 in Review

Broadfin Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2016, closing a stake of 105,780 shares — an estimated $4.46M sold.

Broadfin Capital first reported a position in GNCA in Q1 2015 and held it in 4 quarters. The position peaked at $13.7M in Q2 2015. 59 funds tracked by Wall St. Rank hold GNCA as of Q1 2016.

Broadfin Capital reported no remaining Genocea Biosciences, Inc. position as of Q1 2016 after selling out during the quarter.
Broadfin Capital sold 105,780 Genocea Biosciences, Inc. shares in Q1 2016, an estimated $4.46M.
Broadfin Capital first reported a position in Genocea Biosciences, Inc. in Q1 2015 and held it in 4 quarters.
Broadfin Capital's Genocea Biosciences, Inc. position peaked at $13.7M in Q2 2015.
59 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2016.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.